Article info

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

Authors

  1. Correspondence to Dr Raj Tummala, BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, Maryland, USA; Raj.Tummala{at}astrazeneca.com
View Full Text

Citation

Vital EM, Merrill JT, Morand EF, et al
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

Publication history

  • Received August 27, 2021
  • Accepted January 26, 2022
  • First published March 25, 2022.
Online issue publication 
June 10, 2022

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.